Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer

NCT05972655 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Low Rectal Cancer

Interventions

RADIATION: Modified short-course radiotherapy
DRUG: PD-1 antibody
DRUG: Capecitabine
DRUG: Oxaliplatin

Sponsor

Sir Run Run Shaw Hospital